These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 35988113)

  • 1. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration.
    Zhang D; Lu W; Zhuo Z; Mei H; Wu X; Cui Y
    Discov Oncol; 2022 Aug; 13(1):78. PubMed ID: 35988113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
    Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
    J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of the prognostic signature of alternative splicing revealed the prognostic predictor and immune microenvironment in head and neck squamous cell carcinoma.
    Ye F; Wu P; Zhu Y; Huang G; Tao Y; Liao Z; Guan Y
    Front Genet; 2022; 13():989081. PubMed ID: 36338975
    [No Abstract]   [Full Text] [Related]  

  • 4. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
    Wang Z; Liu H; Gong Y; Cheng Y
    Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma.
    Zhang D; Duan Y; Cun J; Yang Q
    Front Genet; 2019; 10():278. PubMed ID: 30984247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
    Lai J; Yang H; Xu T
    BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
    Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
    J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of alternative splicing events and prognostic signatures in breast cancer.
    Han P; Zhu J; Feng G; Wang Z; Ding Y
    BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
    Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
    Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological significance of prognostic markers for breast cancer based on alternative splicing.
    Xu R; Yang Q
    Am J Transl Res; 2022; 14(6):4229-4250. PubMed ID: 35836866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative splicing event associated with immunological features in bladder cancer.
    Yu X; Luo B; Lin J; Zhu Y
    Front Oncol; 2022; 12():966088. PubMed ID: 36686818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma.
    Zhu L; Wang Z; Sun Y; Giamas G; Stebbing J; Yu Z; Peng L
    Front Oncol; 2021; 11():778637. PubMed ID: 35004299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
    Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
    Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of RNA Modification-Associated Alternative Splicing Signature as an Independent Factor in Head and Neck Squamous Cell Carcinoma.
    Liu J; Deng W; Xiao Z; Huang X; Lin M; Long Z
    J Immunol Res; 2022; 2022():8976179. PubMed ID: 36157883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Prognostic Signature Constructed with Necroptosis-Related lncRNA in Bladder Cancer.
    Yu Z; Lu B; Gao H; Liang R
    J Oncol; 2022; 2022():5643496. PubMed ID: 36425941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation.
    Li L; Yang W; Jia D; Zheng S; Gao Y; Wang G
    Breast Cancer; 2023 Jul; 30(4):666-684. PubMed ID: 37178414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
    Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
    Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.